长江医药控股股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 证券代码：300391 证券简称：长药控股 公告编号：2025-050 1、2025年第一季度报告 经审核，监事会认为董事会编制和审议公司2025年第一季度报告的程序符合法 律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司的实 际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 详情参见与本公告同日披露于巨潮资讯网的《2025年第一季度报告》。 表决情况：赞成：3票；反对：0票；弃权：0票。 表决结果：通过。 2、关于2025年第一季度计提资产减值准备的议案 监事会认为：公司本次计提资产减值准备的决议程序合法，依据充分，符合《企 业会计准则》等相关规定，符合公司实际情况，计提后能更公允地反映公司资产状 况，同意本次计提资产减值准备。 详情参见与本公告同日披露于巨潮资讯网的《关于2025年第一季度计提资产减 值准备的公告》。 长江医药控股股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于2025年4月 ...

证券代码：300391 证券简称：长药控股 公告编号：2025-049 长江医药控股股份有限公司 第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第五届董事会第二十四次 会议于2025年4月25日以现场加通讯表决方式在公司会议室召开，会议通知已于 2025年4月15日以电子邮件方式送达。本次会议由王波先生主持，应参与表决董事 9人，实际参与表决董事9人，其中顾紫光先生、韩庆凯先生以通讯方式出席并表 决。本次会议为董事会定期会议，召集、召开的程序、方式符合有关法律、行政 法规、部门规章、规范性文件和公司章程规定。 2、关于 2025 年第一季度计提资产减值准备的议案 本议案已经公司董事会审计委员会审议通过。 详情参见与本公告同日披露于巨潮资讯网的《关于 2025 年第一季度计提资产 减值准备的公告》。 二、董事会会议审议情况 1、2025 年第一季度报告 本议案的财务报告部分已经公司董事会审计委员会审议通过。 详情参见与本公告同日披露于巨潮资讯网的《2025 ...

Financial Performance - The company's revenue for Q1 2025 was ¥103,683,885.34, representing a 75.46% increase compared to ¥59,091,762.31 in the same period last year[5] - The net loss attributable to shareholders was ¥60,812,317.13, which is a 28.01% increase from a loss of ¥47,505,902.27 in the previous year[5] - The net cash flow from operating activities was -¥71,835,780.49, a decrease of 118.90% compared to -¥32,816,721.93 in the same period last year[5] - The company's basic earnings per share were -¥0.1736, down 28.02% from -¥0.1356 in the same period last year[5] - The weighted average return on equity improved to -13.13%, a 14.59% increase from -27.72% in the previous year[5] - The net profit for the current period was a loss of ¥89,396,554.98, compared to a loss of ¥81,120,269.42 in the previous period, indicating a deterioration in profitability[34] Revenue and Costs - The increase in revenue was primarily driven by the pharmaceutical segment, which saw a significant rise in income[9] - Total operating revenue for the current period reached ¥103,683,885.34, a significant increase from ¥59,091,762.31 in the previous period, representing a growth of approximately 75.4%[33] - Total operating costs increased to ¥164,016,116.81 from ¥89,749,307.79, marking a rise of about 83.0%[34] Shareholder Information - The company reported a total of 20,224 common shareholders at the end of the reporting period[11] - The top shareholder, Changxing Shengshi Fenghua Business Co., Ltd., holds 10.11% of the shares, amounting to 35,423,600 shares[11] Financial Distress and Liabilities - The company's net assets attributable to the parent company as of December 31, 2024, were -432,840,659.21 CNY, with retained earnings at -1,589,707,417.48 CNY, indicating significant financial distress[13] - The total liabilities of the company as of the latest report were 2.553 billion CNY, compared to 2.417 billion CNY in the previous period, reflecting an increase in financial obligations[31] - The company's total equity attributable to shareholders was -493,652,976.34 CNY, highlighting a critical equity deficiency[31] - The company faces significant risks of bankruptcy and delisting if it fails to meet the Shenzhen Stock Exchange's requirements in the upcoming fiscal year[17] Cash Flow and Investments - Cash and cash equivalents at the end of the period totaled ¥3,289,786.32, down from ¥6,301,111.84 at the beginning of the period[39] - The company reported an investment cash inflow of ¥1,320,000.00, while the cash outflow for investment activities was ¥145,439.20, resulting in a net cash flow from investing activities of ¥1,174,560.80[38] - Financing activities generated a net cash flow of ¥68,545,138.96, an increase from ¥31,502,907.79 in the previous period[38] - The company received other cash related to financing activities amounting to ¥71,555,872.71, compared to ¥49,443,197.38 in the previous period[38] Restructuring and Legal Issues - The company entered pre-restructuring on January 20, 2025, with uncertainty regarding its ability to proceed with formal restructuring[14] - The court has ruled for the bankruptcy restructuring of its subsidiary, indicating potential complications for the parent company's operations[14] - As of April 22, 2025, the company's stock was subject to delisting risk warning due to financial performance issues, including negative net profit and net assets[18] Asset Overview - The total assets at the end of the reporting period were ¥2,042,496,723.36, reflecting a 2.34% increase from ¥1,995,717,642.12 at the end of the previous year[5] - The company's total assets amounted to 2.042 billion CNY, showing a slight increase from 1.996 billion CNY previously[31] Product Development - The company did not report any significant new product developments or market expansions during this period[40]

重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司 重要内容提示： 原告嘉兴骏鹰仓实投资合伙企业(有限合伙)与被告长江医药控股股份有限 公司债权人代位权纠纷案，十堰市中级人民法院于2025年4月11日裁定中止诉讼。 本案涉案金额18,947.85万元，预计不会对公司当期损益产生影响。 一、诉讼事项的基本情况 2025年4月18日，长江医药控股股份有限公司（以下简称"公司"）收到湖 北省十堰市中级人民法院送达的民事裁定书。湖北省十堰市中级人民法院所在地 为十堰市张湾区浙江路66号。诉讼各方当事人如下： 证券代码：300391 证券简称：长药控股 公告编号：2025-048 四、其他尚未披露的诉讼仲裁事项 目前，公司及子公司不存在未披露的小额诉讼仲裁事项。 五、本次公告的诉讼、仲裁对公司本期利润或期后利润的可能影响 原告：嘉兴骏鹰仓实投资合伙企业(有限合伙)，委派代表张程程。 被告：长江医药控股股份有限公司，法定代表人胡士会。 第三人：湖北长江大药房连锁有限公司，法定代表人阳勇。 二、有关案件的基本情况 原告嘉兴骏鹰仓实投资 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Group 1 - Changyao Holdings reported a negative net asset for the end of 2024 and has faced three consecutive years of negative net profit, leading to a non-standard audit opinion and potential delisting risk [1] - Hengrui Medicine's second-generation PARP inhibitor HRS-1167 has received clinical trial approval for treating metastatic prostate cancer, indicating potential for broader application in oncology [2] - Baike Biotech's revenue for 2024 decreased by 32.64% to 1.229 billion yuan, with a net profit drop of 53.67% primarily due to reduced sales of its shingles vaccine [3] Group 2 - Kangtai Biological's revenue fell by 23.75% in 2024, with a net profit decline of 76.60%, attributed to market competition and inventory reduction strategies [4] - Changchun High-tech reported a 7.55% decrease in revenue to 13.466 billion yuan for 2024, with a net profit decline of 43.01%, facing challenges from centralized procurement policies and intensified industry competition [5]

中审亚太会计师事务所(特殊普通合伙) China Audit Asia Pacific Certified Public Accountants LLP 计 报 告 AUDIT REPORT 二、注册会计师的责任 China Audit Asia Pacific Certified Public Accountants LLP 内部控制审计报告 中审亚太审字(2025)004792 号 长江医药控股股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了长江医药控股股份有限公司（以下简称"长药控股公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、长药控股公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是长药控股 公司董事会的责任。 长江医药控股股份有限公司 内部控制审计报告 中国 · 北京 BEIJING CHINA 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行 ...

中审亚太会计师事务所 (特殊普通合伙) China Audit Asia Pacific Certified Public Accountants LLP 关于长江医药控股股份有限公司 非经营性资金占用及其他关联资金往来情况 中国・北京 BEIJING CHINA 】 | | | 2、附表 1-2 3 的专项审核报告 中审亚太审字(2025)004793 号 长江医药控股股份有限公司全体股东: 我们接受委托,在审计了长江医药控股股份有限公司(以下简称"长药控股 公司"）2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表和合并及公司股东权益变动表以及财务报表附 注的基础上,对后附的《上市公司 2024年度非经营性资金占用及其他关联资金 往来情况汇总表》(以下简称"汇总表")进行了专项审核。按照中国证券监督 管理委员会、国务院国有资产监督管理委员会印发的《关于规范上市公司与关联 方资金往来及上市公司对外担保若干问题的通知》（证监发[2003]56 号）的规 定,编制和披露汇总表、提供真实、合法、完整的审核证据是长药控股公司管理 层的责任,我们的责任是在 ...

关于长江医药控股股份有限公司 2024 年度营业收入扣除事项的专项审核报告 中审亚太审字(2025)004795 号 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于长江医药控股股份有限公司 2024 年度营业收入扣除事项 的专项审核报告 中国・北京 BEIJING CHINA China Audit Asia Pacific Certified Public Accountants LLP 长江医药控股股份有限公司全体股东: 我们接受委托,在审计了长江医药控股股份有限公司(以下简称"长药控股 公司"）2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表和合并及公司股东权益变动表以及财务报表附 注的基础上,审核了长药控股公司管理层编制的后附 2024年度营业收入扣除情 况明细表（以下简称"明细表"）。 一、 管理层的责任 根据《深圳证券交易所创业板股票上市规则》（2020年12月修订）等相关规 定,长药控股公司管理层在年度报告中披露营业收入扣 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于长江医药控股股份有限公司 2024 年度财务报表非标准审计意见 的专项说明 中国・北京 BEIJING CHINA China Audit Asia Pacific Certified Public Accountants LLP 关于长江医药控股股份有限公司 2024 年度财务报表非标准审计意见的专项说明 中审亚太审字(2025)004794 号 深圳证券交易所: 我们接受委托,对长江医药控股股份有限公司(以下简称"长药控股公司") 2024 年度财务报表进行了审计,并于 2025年 4 月 17 日出具了与持续经营相关 的重大不确定性的无保留意见的审计报告(报告编号:中审亚太审字 (2025)004788 号)。根据中国证券监督管理委员会《公开发行证券的公司信息披 露编报规则第 14 号 -- 非标准审计意见及其涉及事项的处理》、《监管规则适用 指引--审计类第1号》和《深圳证券交易所创业板股票上市规则》等相关要求, 就相关事项说明如下: 一、 合并 ...